{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:11:55Z","timestamp":1771693915414,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01195-9","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:21:31Z","timestamp":1768958491000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6 Inhibition in the Management of Metastatic HR+\/HER2+ Breast Cancer: Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Daniel","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Varda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Yeremian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"8","key":"1195_CR1","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1530\/ERC-21-0293","volume":"29","author":"A Alataki","year":"2022","unstructured":"Alataki A, Dowsett M. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer. Endocr Relat Cancer. 2022;29(8):R105\u201322. https:\/\/doi.org\/10.1530\/ERC-21-0293.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1195_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991\u20131000. https:\/\/doi.org\/10.1038\/s41416-019-0619-y.","journal-title":"Br J Cancer"},{"issue":"2","key":"1195_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-014-3145-x","volume":"148","author":"A Alqaisi","year":"2014","unstructured":"Alqaisi A, et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat. 2014;148(2):437\u201344. https:\/\/doi.org\/10.1007\/s10549-014-3145-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1195_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03680-7","volume":"25","author":"J Xie","year":"2025","unstructured":"Xie J, et al. Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes. Cancer Cell Int. 2025;25(1):77. https:\/\/doi.org\/10.1186\/s12935-025-03680-7.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1195_CR5","first-page":"15","volume":"149","author":"J Geradts","year":"1996","unstructured":"Geradts J, Wilson PA. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 1996;149(1):15\u201320.","journal-title":"Am J Pathol"},{"issue":"6","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(20)30112-1.","journal-title":"Lancet Oncol"},{"key":"1195_CR7","unstructured":"Patel R, Cascetta K, Klein P, et al. A multicenter, phase I\/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE). Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, Dec. 05, 2023."},{"issue":"24","key":"1195_CR8","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-23-0117","volume":"29","author":"E Shagisultanova","year":"2023","unstructured":"Shagisultanova E, et al. Safety and efficacy of tucatinib, letrozole, and palbociclib in patients with previously treated HR+\/HER2+ breast cancer. Clin Cancer Res. 2023;29(24):5021\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0117.","journal-title":"Clin Cancer Res"},{"key":"1195_CR9","doi-asserted-by":"publisher","unstructured":"Ciruelos E, Pascual T, Villacampa G, Pernas S, Sanchez-Bayona R, Ponce-Lorenzo JJ. Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer. J Clin Oncol. [Online]. Available: https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1008. Accessed: 15 Mar 2025.","DOI":"10.1200\/JCO.2024.42.16_suppl.1008"},{"issue":"12","key":"1195_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12):926\u201335. https:\/\/doi.org\/10.1093\/jnci\/djh166.","journal-title":"J Natl Cancer Inst"},{"issue":"2 Pt 2","key":"1195_CR11","doi-asserted-by":"publisher","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","volume":"11","author":"CK Osborne","year":"2005","unstructured":"Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11(2 Pt 2):865s-s870.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1195_CR12","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-0740-3","volume":"10","author":"Z Yang","year":"2004","unstructured":"Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res. 2004;10(11):3621\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-0740-3.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1195_CR13","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","volume":"21","author":"M Giuliano","year":"2015","unstructured":"Giuliano M, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res. 2015;21(17):3995\u20134003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2728.","journal-title":"Clin Cancer Res"},{"issue":"7\u20138","key":"1195_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18632\/genesandcancer.24","volume":"5","author":"AK Witkiewicz","year":"2014","unstructured":"Witkiewicz AK, Cox D, Knudsen ES. CDK4\/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014;5(7\u20138):261\u201372.","journal-title":"Genes Cancer"},{"issue":"5","key":"1195_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. https:\/\/doi.org\/10.1186\/bcr2419.","journal-title":"Breast Cancer Res"},{"key":"1195_CR16","unstructured":"Metzger O. AFT-38 PATINA: a randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive (HR+)\/HER2-positive metastatic breast cancer. In: San Antonio Breast Cancer Symposium, 2024."},{"key":"1195_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.298","volume":"35","author":"W Janni","year":"2024","unstructured":"Janni W, et al. 350MO omission of chemotherapy and addition of the CDK4\/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer \u2013 second interim efficacy analysis of the randomized phase III DETECT V trial. Ann Oncol. 2024;35:S362. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.298.","journal-title":"Ann Oncol"},{"issue":"3","key":"1195_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, et al. Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"issue":"4","key":"1195_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jnci\/djy109","volume":"111","author":"V Di\u00e9ras","year":"2019","unstructured":"Di\u00e9ras V, et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2\u2212 advanced breast cancer. J Natl Cancer Inst. 2019;111(4):419\u201330. https:\/\/doi.org\/10.1093\/jnci\/djy109.","journal-title":"J Natl Cancer Inst"},{"key":"1195_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100691","volume":"35","author":"MQN Hackert","year":"2023","unstructured":"Hackert MQN, et al. Real-world palbociclib effectiveness in patients with metastatic breast cancer: focus on neutropenia-related treatment modification strategies and clinical outcomes. Cancer Treat Res Commun. 2023;35:100691. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100691.","journal-title":"Cancer Treat Res Commun"},{"issue":"25","key":"1195_CR21","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1195_CR22","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1195_CR23","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53\u201365. https:\/\/doi.org\/10.1002\/onco.13531.","journal-title":"Oncologist"},{"issue":"1","key":"1195_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0121-y","volume":"5","author":"A Marra","year":"2019","unstructured":"Marra A, Curigliano G. Are all cyclin-dependent kinases 4\/6 inhibitors created equal? NPJ Breast Cancer. 2019;5(1):27. https:\/\/doi.org\/10.1038\/s41523-019-0121-y.","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"1195_CR25","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1007\/s00520-016-3217-z","volume":"24","author":"C Ecclestone","year":"2016","unstructured":"Ecclestone C, et al. Quality of life and symptom burden in patients with metastatic breast cancer. Support Care Cancer. 2016;24(9):4035\u201343. https:\/\/doi.org\/10.1007\/s00520-016-3217-z.","journal-title":"Support Care Cancer"},{"issue":"12","key":"1195_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.18553\/jmcp.2025.31.12.1285","volume":"31","author":"T Kiener","year":"2025","unstructured":"Kiener T, Li KH, Chiang E, Le QA. Impact of CDK4\/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: a systematic review and meta-analysis. JMCP. 2025;31(12):1285\u2013303. https:\/\/doi.org\/10.18553\/jmcp.2025.31.12.1285.","journal-title":"JMCP"},{"issue":"10","key":"1195_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/oncolo\/oyad207","volume":"28","author":"F Cardoso","year":"2023","unstructured":"Cardoso F, et al. Quality of life and treatment-related side effects in patients with HR+\/HER2\u2212 advanced breast cancer: findings from a multicountry survey. Oncologist. 2023;28(10):856\u201365. https:\/\/doi.org\/10.1093\/oncolo\/oyad207.","journal-title":"Oncologist"},{"issue":"3","key":"1195_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx784.","journal-title":"Ann Oncol"},{"key":"1195_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.895729","volume":"13","author":"SA Jeffreys","year":"2022","unstructured":"Jeffreys SA, et al. Prognostic and predictive value of CCND1\/cyclin D1 amplification in breast cancer with a focus on postmenopausal patients: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:895729. https:\/\/doi.org\/10.3389\/fendo.2022.895729.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1195_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox M, et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer. Nat Commun. 2022;13(1):5258. https:\/\/doi.org\/10.1038\/s41467-022-32828-6.","journal-title":"Nat Commun"},{"issue":"10","key":"1195_CR31","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.7150\/jca.111362","volume":"16","author":"S-F Wang","year":"2025","unstructured":"Wang S-F, et al. Impact of PIK3CA mutations on the clinical benefits of CDK 4\/6 inhibitors in HR+\/HER2\u2212 advanced breast cancer: an updated pairwise and network meta-analysis. J Cancer. 2025;16(10):3065\u201379. https:\/\/doi.org\/10.7150\/jca.111362.","journal-title":"J Cancer"},{"issue":"1","key":"1195_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci C, et al. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer. 2018;4(1):38. https:\/\/doi.org\/10.1038\/s41523-018-0092-4.","journal-title":"NPJ Breast Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01195-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01195-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01195-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:09Z","timestamp":1771692429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01195-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01195-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel Park, Marian Varda, Sofia Yeremian, Andrew Hwang, and Charity Huang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DP: methodology, literature review, analysis, manuscript writing. MV: manuscript writing, review and editing. SY: literature review, manuscript writing, review and editing. AH: conceptualization, manuscript writing, review and editing. CH: conceptualization, methodology, manuscript writing, review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}